Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.
Biosimilars will be one of three key business areas for Samsung Biologics, the company has confirmed, in the wake of its decision earlier this year to buy out partner Biogen’s “50% -1” equity stake in the pair’s Samsung Bioepis biosimilars joint venture.
Announced at the end of January (see sidebar), the transaction is worth up to $2.3bn and followed rumors late last...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
